JPWO2019158572A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019158572A5 JPWO2019158572A5 JP2020543611A JP2020543611A JPWO2019158572A5 JP WO2019158572 A5 JPWO2019158572 A5 JP WO2019158572A5 JP 2020543611 A JP2020543611 A JP 2020543611A JP 2020543611 A JP2020543611 A JP 2020543611A JP WO2019158572 A5 JPWO2019158572 A5 JP WO2019158572A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- -1 1-fluoromethyl-cyclopropylmethoxy Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 229910014033 C-OH Inorganic materials 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 229910014570 C—OH Inorganic materials 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 201000005624 HELLP Syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 102000003623 TRPC6 Human genes 0.000 claims 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630907P | 2018-02-15 | 2018-02-15 | |
| US62/630,907 | 2018-02-15 | ||
| PCT/EP2019/053525 WO2019158572A1 (en) | 2018-02-15 | 2019-02-13 | Inhibitors of trpc6 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513984A JP2021513984A (ja) | 2021-06-03 |
| JPWO2019158572A5 true JPWO2019158572A5 (https=) | 2022-02-22 |
| JP2021513984A5 JP2021513984A5 (https=) | 2022-02-22 |
| JP7291711B2 JP7291711B2 (ja) | 2023-06-15 |
Family
ID=65496750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543611A Active JP7291711B2 (ja) | 2018-02-15 | 2019-02-13 | Ｔｒｐｃ６阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11485740B2 (https=) |
| EP (1) | EP3752499B1 (https=) |
| JP (1) | JP7291711B2 (https=) |
| CN (1) | CN111770918B (https=) |
| WO (1) | WO2019158572A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011632RA (en) * | 2017-10-27 | 2021-01-28 | Boehringer Ingelheim Int | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
| WO2019241131A1 (en) | 2018-06-11 | 2019-12-19 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| US12054487B2 (en) | 2018-09-04 | 2024-08-06 | Contineum Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| IL326597A (en) * | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| AR121846A1 (es) | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
| JP7502462B2 (ja) * | 2020-04-16 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器状態を処置するためのｔｒｐｃ６阻害剤 |
| US20250042873A1 (en) * | 2021-08-24 | 2025-02-06 | The Johns Hopkins University | Compositions and methods for treating proteotoxicity-associated diseases |
| CN121729232A (zh) * | 2023-08-18 | 2026-03-24 | 勃林格殷格翰国际有限公司 | 用于治疗局灶节段性肾小球硬化症的trpc6抑制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040010713A (ko) * | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| CN102970965A (zh) | 2010-04-05 | 2013-03-13 | Sk化学公司 | 含有pde5抑制剂的减少皮肤皱纹的合成物 |
| GB2497476B (en) * | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
| WO2012037349A2 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
| EP2556829B1 (en) * | 2011-08-10 | 2015-08-19 | Universität Leipzig | Bicyclic labdane diterpenes for use in the treatment of TRPC6 associated diseases |
| WO2014192865A1 (ja) * | 2013-05-30 | 2014-12-04 | 大日本住友製薬株式会社 | フェニルピペラジン誘導体 |
| CN103694242B (zh) * | 2013-12-10 | 2016-01-06 | 昆明翔昊科技有限公司 | 吡唑并嘧啶类化合物及其药物组合物和其在制药中的应用 |
| CN107253952B (zh) * | 2017-08-01 | 2019-07-30 | 烟台大学 | 具有抗胃癌活性的trpc6抑制剂及其制备方法和用途 |
| SG10202011632RA (en) * | 2017-10-27 | 2021-01-28 | Boehringer Ingelheim Int | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
| CN111868055B (zh) * | 2018-02-16 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Trpc6的抑制剂 |
| JP7585227B2 (ja) * | 2019-04-12 | 2024-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| JP7502462B2 (ja) * | 2020-04-16 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器状態を処置するためのｔｒｐｃ６阻害剤 |
-
2019
- 2019-02-13 JP JP2020543611A patent/JP7291711B2/ja active Active
- 2019-02-13 US US16/970,129 patent/US11485740B2/en active Active
- 2019-02-13 EP EP19706258.1A patent/EP3752499B1/en active Active
- 2019-02-13 WO PCT/EP2019/053525 patent/WO2019158572A1/en not_active Ceased
- 2019-02-13 CN CN201980013417.2A patent/CN111770918B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513984A5 (https=) | ||
| JPWO2019158572A5 (https=) | ||
| JP2018519357A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| JP2019514882A5 (https=) | ||
| JP2020515574A5 (https=) | ||
| RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
| JP2015501782A5 (https=) | ||
| JP2009534457A5 (https=) | ||
| JP2017530959A5 (https=) | ||
| JP2010522765A5 (https=) | ||
| JP2019519476A5 (https=) | ||
| JP2018509438A5 (https=) | ||
| JP2019514883A5 (https=) | ||
| JP2010528089A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2021500390A5 (https=) | ||
| JP2017502006A5 (https=) | ||
| JP2018529745A5 (https=) | ||
| JP2012515182A (ja) | Ｓ１ｐ１受容体アゴニストとしてのオキサジアゾール誘導体 | |
| JP2020502047A5 (https=) | ||
| JP2013502441A5 (https=) | ||
| JP2014504646A5 (https=) | ||
| JP2011510068A5 (https=) | ||
| JP2020512400A5 (https=) |